Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. MasterCard (MA) upgraded to Buy from Neutral at Guggenheim. 2. FireEye (FEYE) upgraded to Overweight from Equal Weight at Stephens with analyst Jonathan Ruykhaver saying he believes consensus expectations are modeling a decline in product revenue this year, though he thinks this is too low given the refresh opportunity from appliance sales about 3 years ago. 3. Teva (TEVA) upgraded to Buy from Neutral at BTIG with analyst Timothy Chiang saying the company's appointment of Kare Schultz as its new CEO is "a positive catalyst that should help create a floor for the shares and provide a boost to near-term investor sentiment." 4. Incyte (INCY) upgraded to Outperform from Market Perform at Raymond James with analyst Reni Benjamin citing increased confidence in the probability of success of the ongoing Phase III ECHO-301, Epa plus pembrolizumab study, the commercial prospects of the Epa franchise in melanoma and at least four other tumor types, as well as the U.S. commercial opportunity for baricitinib. 5. QuickLogic (QUIK) upgraded to Buy from Neutral at Roth Capital with analyst Suji Desilva saying he believes its revenues are better positioned for upside revisions. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.